No­vo Nordisk touts an­oth­er once-week­ly in­sulin win; Mere­o's board bat­tle heats up again

No­vo Nordisk has com­plet­ed the post­ing of topline re­sults across its six Phase II­Ia clin­i­cal tri­als in the ON­WARDS pro­gram, round­ing out a full-fledged ef­fort to bring an­oth­er di­a­betes treat­ment to mar­ket.

In ON­WARDS 5, once-week­ly in­sulin icodec was found to be non-in­fe­ri­or to once-dai­ly basal in­sulin in re­duc­ing HbA1c, the Dan­ish Big Phar­ma re­port­ed Mon­day. With that, the 52-week open-la­bel tri­al met its pri­ma­ry end­point at the end of the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER